36 results on '"Zhong, Jin"'
Search Results
2. Identification and characterization of Sofosbuvir‐resistant mutations of hepatitis C virus genotype 3a replicon.
- Author
-
Ngari, Jackline Wangu, Leumi, Steve, Han, Lin, Liu, Chaolun, Tong, Yimin, and Zhong, Jin
- Subjects
HEPATITIS C virus ,GENETIC mutation ,GENOTYPES ,VIRAL genomes ,VIRAL proteins - Abstract
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease worldwide. Among its 8 genotypes (GT), GT3 has a relatively lower sustained virological response to highly effective direct‐acting antiviral agents (DAA). Sofosbuvir (SOF), an anti‐NS5B polymerase inhibitor, is a core component of many anti‐HCV DAA cocktail regimens, and its resistant mutations are rare in clinics because these mutations usually severely impair the NS5B polymerase activity, including a mutation S282T in NS5B, the most frequently reported SOF‐resistant mutation. In this study, we selected SOF‐resistant variants of a previously developed GT3 subgenomic replicon (PR87A7). Two mutations were identified in the viral genome of SOF‐resistant PR87A7 variants, Q606R in nontargeted NS3 and S282T in targeted N5SB. We demonstrated that Q606R could rescue the replication defect of S282T in PR87A7, and the resulting double mutant confers the SOF resistance. Finally, we showed that NS3‐606R could not compensate for the replication defect of S282T in other GTs. In conclusion, we identified a novel GT3‐specific combination of two mutations that confers SOF resistance. Our result calls for attention to potential mutations that may arise in nontargeted viral proteins during the SOF‐based DAA treatment of chronic HCV. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Construction and characterization of a new hepatitis C virus genotype 6a subgenomic replicon that is prone to render the sofosbuvir resistance.
- Author
-
Liu, Chaolun, Guo, Mingzhe, Han, Lin, Lu, Jie, Xiang, Xiaogang, Xie, Qing, Nouhin, Janin, Duong, Veasna, Tong, Yimin, and Zhong, Jin
- Subjects
HEPATITIS C virus ,SOFOSBUVIR ,AMINO acid residues ,GENOTYPES ,RNA polymerases - Abstract
Hepatitis C virus (HCV) infection remains a challenge to human public health despite the development of highly effective direct‐acting antivirals (DAAs). Sofosbuvir (SOF), a key component in most DAA‐based anti‐HCV cocktail regimens, is a potent viral RNA polymerase (NS5B) inhibitor with a high barrier to drug resistance. The serine‐to‐threonine mutation at NS5B 282 (S282T) confers the SOF resistance, but severely impairs viral replication in most HCV genotypes (GTs) and cannot be stably maintained after the termination of the SOF‐based therapies. In this study, we first developed a new HCV GT‐6a subgenomic replicon PR58D6. Next, we selected SOF‐resistant PR58D6 variants by culturing the replicon cells in the presence of SOF. Interestingly, unlike many other HCV replicons which require additional mutations to compensate for the S282T‐inducing fitness loss, S282T alone in PR58D6 is genetically stable and confers the SOF resistance without significantly impairing viral replication. Furthermore, we showed that amino acid residue at NS5B 74 (R74) and 556 (D556) which are conserved in GT 6a HCV contribute to efficient replication of PR58D6 containing S282T. Finally, we showed that the G556D mutation in NS5B could rescue the replication deficiency of the S282T in JFH1, a GT‐2a replicon. In conclusion, we showed that a novel GT‐6a HCV replicon may easily render SOF resistance, which may call for attention to potential drug resistance during DAA therapies of HCV GT‐6a patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Double-Stranded DNA and Double-Stranded RNA Induce a Common Antiviral Signaling Pathway in Human Cells
- Author
-
Cheng, Guofeng, Zhong, Jin, Chung, Josan, and Chisari, Francis V.
- Published
- 2007
- Full Text
- View/download PDF
5. Hepatitis C virus genotype 4: A poorly characterized endemic genotype.
- Author
-
Leumi, Steve, El Kassas, Mohamed, and Zhong, Jin
- Subjects
HEPATITIS C virus ,GENETIC variation ,GENOTYPES ,PHYSICIANS - Abstract
Globally, 13% of all hepatitis C virus (HCV) infections are caused by genotype 4 (GT4), which consists of 17 subtypes with various levels of susceptibility to anti‐HCV therapy. This genotype is endemic in the Middle East and Africa and has considerably spread to Europe lately. The molecular features of HCV‐GT4 infection, as well as its appropriate therapeutics, are poorly characterized as it has not been the subject of widespread basic research. As such, in this review, we aim to gather the current state of knowledge of this genotype with a particular emphasis on its heterogeneity, sequence signatures, resistance‐associated substitutions, and available in vivo and in vitro models used for its study. We urge developing more cell‐culture models based on different GT4 subtypes to better understand the virology and therapeutic response of this particular genotype. This review may raise more awareness about this genotype and trigger more basic research work to develop its research tools. This will be critical to design better therapeutics and help to provide adequate guidelines for physicians working with HCV‐GT4 patients. Highlights: We raised awarness on the fast growing prevalence of HCV‐GT4 beyong the endemic region.We analysed the genetic diversity of GT4 subtypes.We summarized the succeptibility of HCV‐GT4 to the current standart treatment.We reported the GT4‐specific sequence signatures.We summarized the availabe in vivo and in vitro research tools for study HCV‐GT4. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
6. Glycometabolism regulates hepatitis C virus release.
- Author
-
Yu, Tao, Yang, Qiankun, Tian, Fangling, Chang, Haishuang, Hu, Zhenzheng, Yu, Bowen, Han, Lin, Xing, Yifan, Jiu, Yaming, He, Yongning, and Zhong, Jin
- Subjects
HEPATITIS C virus ,GLYCOLYSIS ,CELL culture ,CELL lines ,CELL cycle ,OXIDATIVE phosphorylation - Abstract
HCV cell-culture system uses hepatoma-derived cell lines for efficient virus propagation. Tumor cells cultured in glucose undergo active aerobic glycolysis, but switch to oxidative phosphorylation for energy production when cultured in galactose. Here, we investigated whether modulation of glycolysis in hepatocytes affects HCV infection. We showed HCV release, but not entry, genome replication or virion assembly, is significantly blocked when cells are cultured in galactose, leading to accumulation of intracellular infectious virions within multivesicular body (MVB). Blockade of the MVB-lysosome fusion or treatment with pro-inflammatory cytokines promotes HCV release in galactose. Furthermore, we found this glycometabolic regulation of HCV release is mediated by MAPK-p38 phosphorylation. Finally, we showed HCV cell-to-cell transmission is not affected by glycometabolism, suggesting that HCV cell-to-supernatant release and cell-to-cell transmission are two mechanistically distinct pathways. In summary, we demonstrated glycometabolism regulates the efficiency and route of HCV release. We proposed HCV may exploit the metabolic state in hepatocytes to favor its spread through the cell-to-cell transmission in vivo to evade immune response. Author summary: Hepatitis C virus (HCV) is a positive-stranded RNA virus that causes acute and chronic hepatitis and hepatocellular carcinoma. HCV infectious cycle comprises viral entry, uncoating, translation and replication of viral RNA, assembly into new virions and release. Establishment of HCV cell culture system (HCVcc) has yielded many insights into complete HCV infectious cycle in Huh7 cell and Huh7-derived human hepatoma cell lines. However, because hepatoma-derived cell lines and hepatocytes vary in metabolism, HCV infectious cycle in tumor cell lines and the patient's liver may also be different. Therefore, we explored the alterations of HCV infectious cycle by forcing the tumor cell lines to switch their glycometabolic pathways. We found that HCV release can be blocked by culturing cells in galactose-containing medium, leading to accumulation of intracellular infectious virions within MVB. Moreover, we provided new evidence to suggest that HCV cell-to-cell transmission may be mechanistically distinct from cell-to-supernatant release. Finally, we proposed a new concept that HCV release from hepatocytes into circulation may be naturally inefficient due to the metabolic state in liver that may favor more HCV cell-to-cell transmission. This strategy would allow HCV to effectively evade neutralizing antibodies to establish persistent infection. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
7. A Nanoparticle-Based Hepatitis C Virus Vaccine With Enhanced Potency.
- Author
-
Yan, Yu, Wang, Xuesong, Lou, Peilan, Hu, Zhenzheng, Qu, Panke, Li, Dapeng, Li, Qingchao, Xu, Yongfen, Niu, Junqi, He, Yongning, Zhong, Jin, and Zhong, Huang
- Subjects
HEPATITIS C virus ,VIRAL vaccines ,CHIMERIC proteins ,ANIMAL experimentation ,COMPARATIVE studies ,HEPATITIS viruses ,VIRAL hepatitis ,IMMUNIZATION ,IMMUNOGLOBULINS ,INSECTS ,RESEARCH methodology ,MEDICAL cooperation ,MICE ,NANOPARTICLES ,PROTEINS ,RECOMBINANT proteins ,RESEARCH ,VACCINES ,VIRAL antibodies ,EVALUATION research ,CHRONIC hepatitis C ,GENOTYPES - Abstract
Despite the emergence of new direct-acting antivirals, hepatitis C virus (HCV) chronic infection and its consequent fibrosis and hepatocarcinoma remain a significant burden for public health, thus requiring an effective preventive vaccine. Our group previously showed that a subunit vaccine based on recombinant soluble E2 (sE2) can induce broadly neutralizing antibodies. To improve the immunogenicity of sE2, we designed and produced a fusion protein (sE2-ferritin) comprising sE2 and a ferritin unit in Drosophila S2 cells, which self-assembled into a nanoparticle with sE2 displayed on the surface. The sE2 moiety on the sE2-ferritin nanoparticle not only had nearly natural conformation but also had better affinities than the unfused sE2 to neutralizing antibodies, receptor, and patient serum. Mouse immunization studies showed that sE2-ferritin was more potent than sE2 in inducing anti-HCV broadly neutralizing antibodies. Our results demonstrate that sE2-ferritin is a vaccine candidate superior to previously developed sE2, providing a new possibility for controlling HCV. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
8. Functional expression and characterization of the envelope glycoprotein E1E2 heterodimer of hepatitis C virus.
- Author
-
Cao, Longxing, Yu, Bowen, Kong, Dandan, Cong, Qian, Yu, Tao, Chen, Zibo, Hu, Zhenzheng, Chang, Haishuang, Zhong, Jin, Baker, David, and He, Yongning
- Subjects
GLYCOPROTEINS ,HEPATITIS C ,HEPATITIS C virus ,FLAVIVIRUSES ,VACCINATION - Abstract
Hepatitis C virus (HCV) is a member of Hepacivirus and belongs to the family of Flaviviridae. HCV infects millions of people worldwide and may lead to cirrhosis and hepatocellular carcinoma. HCV envelope proteins, E1 and E2, play critical roles in viral cell entry and act as major epitopes for neutralizing antibodies. However, unlike other known flaviviruses, it has been challenging to study HCV envelope proteins E1E2 in the past decades as the in vitro expressed E1E2 heterodimers are usually of poor quality, making the structural and functional characterization difficult. Here we express the ectodomains of HCV E1E2 heterodimer with either an Fc-tag or a de novo designed heterodimeric tag and are able to isolate soluble E1E2 heterodimer suitable for functional and structural studies. Then we characterize the E1E2 heterodimer by electron microscopy and model the structure by the coevolution based modeling strategy with Rosetta, revealing the potential interactions between E1 and E2. Moreover, the E1E2 heterodimer is applied to examine the interactions with the known HCV receptors, neutralizing antibodies as well as the inhibition of HCV infection, confirming the functionality of the E1E2 heterodimer and the binding profiles of E1E2 with the cellular receptors. Therefore, the expressed E1E2 heterodimer would be a valuable target for both viral studies and vaccination against HCV. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
9. Role of Hepatitis C Virus Envelope Glycoprotein E1 in Virus Entry and Assembly.
- Author
-
Tong, Yimin, Lavillette, Dimitri, Li, Qingchao, and Zhong, Jin
- Subjects
HEPATITIS C virus ,GLYCOPROTEINS ,VIROLOGY - Abstract
Hepatitis C virus (HCV) glycoproteins E1 and E2 form a heterodimer to constitute viral envelope proteins, which play an essential role in virus entry. E1 does not directly interact with host receptors, and its functions in viral entry are exerted mostly through its interaction with E2 that directly binds the receptors. HCV enters the host cell
via receptor-mediated endocytosis during which the fusion of viral and host endosomal membranes occurs to release viral genome to cytoplasm. A putative fusion peptide in E1 has been proposed to participate in membrane fusion, but its exact role and underlying molecular mechanisms remain to be deciphered. Recently solved crystal structures of the E2 ectodomains and N-terminal of E1 fail to reveal a classical fusion-like structure in HCV envelope glycoproteins. In addition, accumulating evidence suggests that E1 also plays an important role in virus assembly. In this mini-review, we summarize current knowledge on HCV E1 including its structure and biological functions in virus entry, fusion, and assembly, which may provide clues for developing HCV vaccines and more effective antivirals. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
10. Hepatitis C Virus Infection and Vaccine Development.
- Author
-
Guo, Xuan, Zhong, Jin-Yi, and Li, Jun-Wen
- Subjects
- *
HEPATITIS C virus , *HEPATITIS C vaccines , *VACCINE effectiveness , *DRUG development , *DNA vaccines - Abstract
In the twenty-seven years since the discovery of hepatitis C virus (HCV) the majority of individuals exposed to HCV establish a persistent infection, which is a leading cause of chronic liver disease, cirrhosis and hepatocellular carcinoma. In developed nations, the cure rates of HCV infection could be over 90% with direct-acting antiviral (DAA) regimens, which has made the great progress in global eradication. However, the cost of these treatments is so expensive that the patients in developing nations, where the disease burden is the most severe, could not afford it, which highly restricted its access. Additionally, the largely asymptomatic nature of infection facilitates continued transmission in risk groups due to limited surveillance. Consequently a protective vaccine and likely emergence of drug-resistant viral variants call for further studies of HCV biology. In the current review, the development and the progress of preventive and therapeutic vaccines against the HCV have been reviewed in the context of peptide vaccines, recombinant protein vaccines, HCV-like particle, DNA vaccines and viral vectors expressing HCV genes. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
11. Hepatitis C virus NS4B induces the degradation of TRIF to inhibit TLR3-mediated interferon signaling pathway.
- Author
-
Liang, Yisha, Cao, Xuezhi, Ding, Qiang, Zhao, Yanan, He, Zhenliang, and Zhong, Jin
- Subjects
HEPATITIS C virus ,TOLL-like receptors ,PROTEOLYSIS ,INTERFERONS ,ADAPTOR proteins ,CASPASES ,IMMUNE response - Abstract
Toll-like receptor 3 (TLR3) senses dsRNA intermediates produced during RNA virus replication to activate innate immune signaling pathways through adaptor protein TRIF. Many viruses have evolved strategies to block TLR3-mediated interferon signaling via targeting TRIF. Here we studied how hepatitis C virus (HCV) antagonizes the TLR3-mediated interferon signaling. We found that HCV-encoded NS4B protein inhibited TLR3-mediated interferon signaling by down-regulating TRIF protein level. Mechanism studies indicated that the downregulation of TRIF by NS4B was dependent on caspase8. NS4B transfection or HCV infection can activate caspase8 to promote TRIF degradation, leading to suppression of TLR3-mediated interferon signaling. Knockout of caspase8 can prevent TRIF degradation triggered by NS4B, thereby enhancing the TLR3-mediated interferon signaling activation in response to HCV infection. In conclusion, our work revealed a new mechanism for HCV to evade innate immune response by blocking the TLR3-mediated interferon signaling via NS4B-induced TRIF degradation. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
12. Immunization With a Subunit Hepatitis C Virus Vaccine Elicits Pan-Genotypic Neutralizing Antibodies and Intrahepatic T-Cell Responses in Nonhuman Primates.
- Author
-
Dapeng Li, Xuesong Wang, von Schaewen, Markus, Wanyin Tao, Yunfang Zhang, Heller, Brigitte, Hrebikova, Gabriela, Qiang Deng, Qiang Sun, Ploss, Alexander, Jin Zhong, Zhong Huang, Li, Dapeng, Wang, Xuesong, Tao, Wanyin, Zhang, Yunfang, Deng, Qiang, Sun, Qiang, Zhong, Jin, and Huang, Zhong
- Subjects
IMMUNIZATION ,HEPATITIS C vaccines ,IMMUNOGLOBULINS ,T cell differentiation ,PRIMATE diseases ,DRUG resistance in bacteria ,ANTIVIRAL agents - Abstract
Background: The global control of hepatitis C virus (HCV) infection remains a great burden, owing to the high prices and potential drug resistance of the new direct-acting antivirals (DAAs), as well as the risk of reinfection in DAA-cured patients. Thus, a prophylactic vaccine for HCV is of great importance. We previously reported that a single recombinant soluble E2 (sE2) vaccine produced in insect cells was able to induce broadly neutralizing antibodies (NAbs) and prevent HCV infection in mice. Here the sE2 vaccine was evaluated in non-human primates.Methods: Rhesus macaques were immunized with sE2 vaccine in combination with different adjuvants. Vaccine-induced NAbs in antisera were tested for neutralization activities against a panel of cell culture-derived HCV (HCVcc), while T-cell responses were evaluated in splenocytes, peripheral blood mononuclear cells, and hepatic lymphocytes.Results: sE2 is able to elicit NAbs against HCVcc harboring structural proteins from multiple HCV genotypes in rhesus macaques. Moreover, sE2-immunized macaques developed systemic and intrahepatic memory T cells specific for E2. A significant correlation between the sE2-specific immunoglobulin G titers and neutralization spectrum was observed, highlighting the essential role of sE2 immunogenicity on achieving broad NAbs.Conclusions: sE2 is a promising HCV vaccine candidate that warrants further preclinical and clinical development. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
13. Comprehensive mapping of antigen specific T cell responses in hepatitis C virus infected patients with or without spontaneous viral clearance.
- Author
-
Zhang, Chao, Hua, Rui, Cui, Yuanyuan, Wang, Shasha, Yan, Hongqing, Li, Dongmei, Zhang, Yonghong, Tu, Zhengkun, Hao, Pei, Chen, Xinyue, Zhong, Jin, Niu, Junqi, and Jin, Xia
- Subjects
T cells ,HEPATITIS C ,ANTIGENS ,IMMUNE response ,EPITOPES - Abstract
Elucidating protective immunity against HCV is important for the development of a preventative vaccine. We hypothesize that spontaneous resolution of acute HCV infection offers clue to protective immune responses, and that DAA therapy affects the quality and quantity of HCV-specific T cell responses. To test these hypotheses, we performed T cell epitope mapping in 111 HCV-infected individuals including 61 chronically HCV-1b (CHC-1b) infected, 24 chronically HCV-2a (CHC-2a) infected and 26 spontaneously recovered (SPR) patients with 376 overlapping peptides covering the entire HCV polyprotein. Selected T cell epitopes were then used to evaluate T cell responses in another 22 chronically HCV-1b infected patients on DAA therapy. Results showed that SPR had better HCV-specific T cell responses than CHC, as manifested by higher response rate, greater magnitude and broader epitope coverage. In addition, SPR recognized novel epitopes in Core, E1, E2, NS4B, NS5A regions that were not present in the CHC. Furthermore, during the first 24 weeks of DAA therapy, there was no functional immune reconstitution of HCV-specific T cells. These results indicate that T cell responses may be a correlate of protection. Therefore, effective preventative vaccines should elicit a robust T cell response. Although various DAA regimens efficiently cleared viruses from the blood of HCV-infected patients, there was no contemporaneous early T cell immune reconstitution, suggesting that early treatment is needed for preserving the functions of HCV-specific T cells. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
14. Replication Inhibition of Hepatitis B Virus and Hepatitis C Virus in Co-Infected Patients in Chinese Population.
- Author
-
Yu, Ge, Chi, Xiumei, Wu, Ruihong, Wang, Xiaomei, Gao, Xiuzhu, Kong, Fei, Feng, Xiangwei, Gao, Yuanda, Huang, Xinxing, Jin, Jinglan, Qi, Yue, Tu, Zhengkun, Sun, Bing, Zhong, Jin, Pan, Yu, and Niu, Junqi
- Subjects
DNA replication ,HEPATITIS B virus ,HEPATITIS C virus ,MIXED infections ,LIVER injuries ,GENETICS - Abstract
Background: Hepatitis B virus (HBV) and hepatitis C virus (HCV) co-infections contributes to a substantial proportion of liver disease worldwide. The aim of this study was to assess the clinical and virological features of HBV-HCV co-infection. Methods: Demographic data were collected for 3238 high-risk people from an HCV-endemic region in China. Laboratory tests included HCV antibody and HBV serological markers, liver function tests, and routine blood analysis. Anti-HCV positive samples were analyzed for HCV RNA levels and subgenotypes. HBsAg-positive samples were tested for HBV DNA. Results: A total of 1468 patients had chronic HCV and/or HBV infections. Among them, 1200 individuals were classified as HCV mono-infected, 161 were classified as HBV mono-infected, and 107 were classified as co-infected. The HBV-HCV co-infected patients not only had a lower HBV DNA positive rate compared to HBV mono-infected patients (84.1% versus 94.4%, respectively; P<0.001). The median HCV RNA levels in HBV-HCV co-infected patients were significantly lower than those in the HCV mono-infected patients (1.18[Interquartile range (IQR) 0–5.57] versus 5.87[IQR, 3.54–6.71] Log
10 IU/mL, respectively; P<0.001). Furthermore, co-infected patients were less likely to have detectable HCV RNA levels than HCV mono-infected patients (23.4% versus 56.5%, respectively; P<0.001). Those HBV-HCV co-infected patients had significantly lower median HBV DNA levels than those mono-infected with HBV (1.97[IQR, 1.3–3.43] versus 3.06[IQR, 2–4.28] Log10 IU/mL, respectively; P<0.001). The HBV-HCV co-infection group had higher ALT, AST, ALP, GGT, APRI and FIB-4 levels, but lower ALB and total platelet compared to the HBV mono-infection group, and similar to that of the HCV mono-infected group. Conclusion: These results suggest that co-infection with HCV and HBV inhibits the replication of both viruses. The serologic results of HBV-HCV co-infection in patients suggests more liver injury compared to HBV mono-infected patients, but is similar to HCV mono-infection. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
15. CD24 Ala57Val polymorphism is associated with spontaneous viral clearance in the HCV-infected Chinese population.
- Author
-
Sun, Haibo, Pan, Yu, Wu, Ruihong, Lv, Juan, Chi, Xiumei, Wang, Xiaomei, Tu, ZhengKun, Zhong, Jin, Sun, Bing, Liu, Yang, Jiang, Jing, and Niu, Junqi
- Subjects
GLYCOSYLPHOSPHATIDYLINOSITOL ,VIRAL hepatitis ,HEPATITIS C virus ,GENETIC polymorphisms ,CHINESE people ,LIVER diseases ,DISEASES - Abstract
Background & Aims Host immune response to hepatitis C virus ( HCV) is a vital factor involved in both viral clearance and liver disease pathogenesis. CD24 plays an important role in inflammation and immune response and CD24 polymorphisms are associated with risk and progression of chronic hepatitis B virus infection. Our study evaluated whether CD24 polymorphisms affect HCV clearance. Methods We genotyped 544 chronic hepatitis C ( CHC) patients, 78 spontaneous hepatitis C clearance ( SHC) patients and 215 healthy controls for CD24 gene variants at positions −P534, P170, P1527 and IFNL3 rs12979860 by pyrosequencing. In CHC patients, 362 individuals were treated with a recombinant IFN-α2b/ribavirin combination for 48 weeks and were followed up for an additional 24 weeks. Lymphocyte CD24 expression was analysed by flow cytometry. Results We show that P170 CT and CT/ TT genotypes were over-represented in the SHC group compared to CHC patients (62.8% vs. 47.2% and 75.6% vs. 60.3%, for respective polymorphisms). In multivariate logistic analysis, P170 ( CD24 Ala57Val) polymorphism was an independent predictor of SHC (adjusted OR = 2.11, 95% CI = 1.19-3.73, P = 0.010 for CT genotype; OR = 2.01, 95% CI = 1.15-3.49, P = 0.014 for CT/ TT genotype). No significant associations were found between the CD24 polymorphisms and treatment-induced viral clearance in log-rank analysis and Cox regression analysis. Patients with the CT/ TT genotype had greater T-cell CD24 expression than patients with the CC genotype. Conclusions Our findings suggest that CD24 Ala57Val polymorphism and associated variations in CD24 expression may be an important predictor for SHC, but have no effect on antiviral drug treatment response in Chinese CHC patients. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
16. HCV Genomic RNA Activates the NLRP3 Inflammasome in Human Myeloid Cells.
- Author
-
Chen, Wei, Xu, Yongfen, Li, Hua, Tao, Wanyin, Xiang, Yu, Huang, Bing, Niu, Junqi, Zhong, Jin, and Meng, Guangxun
- Subjects
HEPATITIS C virus ,INFLAMMATION ,MYELOID leukemia ,GENE transfection ,MONOCYTES ,OLIGOMERIZATION ,VIRION - Abstract
Background: Elevated plasma levels of IL-1β and IL-18 from patients with hepatitis C virus (HCV) infection indicate a possible activation of inflammasome by HCV. Methodology/Principal Findings: To demonstrate whether HCV infection activates the inflammasome, we investigated inflammasome activation from HCV infected hepatic Huh7 cells, or monocytic cells and THP-1 derived macrophages challenged with HCV virions, but no any inflammasome activation was detected in these cells. However, when we transfected HCV genomic RNA into monocytes or macrophages, IL-1β was secreted in a dose-dependent manner. We also detected ASC oligomerization and caspase-1 cleavage in HCV RNA transfected macrophages. Using shRNA-mediated gene silencing or specific inhibitors, we found that HCV RNA-induced IL-1β secretion was dependent on the presence of inflammasome components such as NLRP3, ASC and caspase-1. Furthermore, we also found that RIG-I was dispensable for HCV RNA-induced NLRP3 inflammasome activation, while reactive oxygen species (ROS) production was required. Conclusions: Our results indicate that HCV RNA activates the NLRP3 inflammasome in a ROS-dependent manner, and RIG-I is not required for this process. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
17. Hepatitis C virus NS3/4 A protease blocks IL-28 production.
- Author
-
Ding, Qiang, Huang, Bing, Lu, Jie, Liu, Yong-Jun, and Zhong, Jin
- Abstract
Type I interferons ( IFNs), including IFN-α, -β, and -ω, play a critical role in innate immune responses against viral infection. IFN-λ, including IL-29, IL-28 A, and IL-28 B, recently identified as a new subfamily of IFN named type III IFN, has also been demonstrated to suppress virus replication in vitro and in vivo. However, the molecular mechanisms that regulate the induction of type III IFNs during viral infection remain elusive. Here, we demonstrate that IL-28 ( IFN-λ 2/3) IFN production, similar to type I IFN, represents a primary and direct host response to HCV genomic RNA transfection. IL-28 ( IFN-λ2/3) induction by HCV genomic RNA was dependent upon the activation of NF-κ B and IRF3. We identified a minimal IL-28 promoter region consisting of putative NF-κ B and IRF3-binding sites. Furthermore, we showed that HCV infection can inhibit HCV genomic RNA-induced IL-28 expression, and that the viral NS3/4 A protease activity was responsible for this inhibitory effect. Our results present important evidence for the control of type III IFN response by HCV, and shed more light on the molecular mechanisms underlying the persistence of HCV infection. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
18. Robust hepatitis C virus infection in vitro.
- Author
-
Zhong, Jin, Gastaminza, Pablo, Guofeng Cheng, Kapadia, Sharookh, Kato, Takanobu, Burton, Dennis R., Wieland, Stefan F., Uprichard, Susan F., Wakita, Takaji, and Chisari, Francis V.
- Subjects
- *
VIRUS diseases , *HEPATITIS C virus , *CELL culture , *VACCINES , *CELL lines , *PATHOGENIC microorganisms - Abstract
The absence of a robust cell culture model of hepatitis C virus (HCV) infection has severely limited analysis of the HCV life cycle and the development of effective antivirals and vaccines. Here we report the establishment of a simple yet robust HCV cell culture infection system based on the HCV JFH-1 molecular clone and Huh-7-derived cell lines that allows the production of virus that can be efficiently propagated in tissue culture. This system provides a powerful tool for the analysis of host-virus interactions that should facilitate the discovery of antiviral drugs and vaccines for this important human pathogen. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
19. The Beginning of Ending Hepatitis C Virus: A Summary of the 26th International Symposium on Hepatitis C Virus and Related Viruses.
- Author
-
Shin, Eui-Cheol, Han, Ji Won, Kang, Wonseok, Kato, Takanobu, Kim, Seong-Jun, Zhong, Jin, Kim, Seungtaek, Park, Su-Hyung, Sung, Pil Soo, Watashi, Koichi, Park, Jun Yong, Windisch, Marc P., Oh, Jong-Won, Wakita, Takaji, Han, Kwang-Hyub, and Jang, Sung Key
- Subjects
HEPATITIS C virus ,VIRUSES ,HEPATITIS C ,CIRRHOSIS of the liver ,HEPATOCELLULAR carcinoma ,CHRONIC hepatitis B - Abstract
Hepatitis C virus (HCV) infects ~71 million people worldwide, and 399,000 people die annually due to HCV-related liver cirrhosis and hepatocellular carcinoma. The use of direct-acting antivirals results in a sustained virologic response in >95% of patients with chronic HCV infection. However, several issues remain to be solved to eradicate HCV. At the 26th International Symposium on Hepatitis C Virus and Related Viruses (HCV2019) held in Seoul, South Korea, October 5–8, 2019, virologists, immunologists, and clinical scientists discussed these remaining issues and how we can achieve the elimination of HCV. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
20. Correction: Hepatitis C virus NS4B induces the degradation of TRIF to inhibit TLR3-mediated interferon signaling pathway.
- Author
-
Liang, Yisha, Cao, Xuezhi, Ding, Qiang, Zhao, Yanan, He, Zhenliang, and Zhong, Jin
- Subjects
HEPATITIS C virus ,TOLL-like receptors ,ADAPTOR proteins - Abstract
A correction to the article "Hepatitis C virus NS4B induces the degradation of TRIF to inhibit TLR3-mediated interferon signaling pathway" by Yisha Liang and colleagues is presented.
- Published
- 2018
- Full Text
- View/download PDF
21. Discovery of a fused bicyclic derivative of 4-hydroxypyrrolidine and imidazolidinone as a new anti-HCV agent.
- Author
-
Xing, Yifan, Chen, Ran, Li, Feng, Xu, Bin, Han, Lin, Liu, Chaolun, Tong, Yimin, Jiu, Yaming, Zhong, Jin, and Zhou, Guo-Chun
- Subjects
- *
HEPATITIS C virus , *ZIKA virus infections , *PUBLIC health , *CELL culture - Abstract
Hepatitis C virus (HCV) infection causes severe liver diseases and remains a major global public health concern. Current direct-acting antiviral (DAA)-based therapies that target viral proteins involving HCV genome replication are effective, however a minority of patients still fail to cure HCV, rendering a window to develop additional antivirals particularly targeting host functions involving in HCV infection. Here, we utilized the HCV infection cell culture system (HCVcc) to screen in-house compounds bearing host-interacting preferred scaffold for the antiviral activity. Compound HXL-10 , a novel fused bicyclic derivative of pyrrolidine and imidazolidinone, was identified as a potent anti-HCV agent with a low cytotoxicity and high specificity. Mechanistic studies showed that HXL-10 neither displayed a virucidal effect nor inhibited HCV genomic RNA replication. Instead, HXL-10 might inhibit HCV assembly by targeting host functions. In summary, we developed a novel anti-HCV agent that may potentially offer additive benefits to the current anti-HCV DDA. • HXL-10 , a fused bicyclic ring, is a potent anti-HCV agent with low cytotoxicity. • HXL-10 has no virucidal effect and does not inhibit HCV genomic RNA replication. • HXL-10 likely targets host functions to inhibit HCV assembly. • HXL-10 has no inhibitory activity against DENV and ZIKV infections. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
22. Identification of nucleotides in the 5’UTR and amino acids substitutions that are essential for the infectivity of 5’UTR-NS5A recombinant of hepatitis C virus genotype 1b (strain Con1).
- Author
-
Li, Jinqian, Feng, Shengjun, Liu, Xi, Guo, Mingzhe, Chen, Mingxiao, Chen, Yiyi, Rong, Liang, Xia, Jinyu, Zhou, Yuanping, Zhong, Jin, and Li, Yi-Ping
- Subjects
- *
HEPATITIS C virus , *NUCLEOTIDES , *VIRUS identification , *AMINO acids , *RECOMBINANT viruses - Abstract
Genotype 1b strain Con1 represents an important reference in the study of hepatitis C virus (HCV). Here, we aimed to develop an advanced infectious Con1 recombinant. We found that previously identified mutations A1226G/F1464L/A1672S/Q1773H permitted culture adaption of Con1 Core-NS5A (C-5A) recombinant containing 5’UTR and NS5B-3’UTR from JFH1 (genotype 2a), thus acquired additional mutations L725H/F886L/D2415G. C-5A containing all seven mutations (C-5A_7m) replicated efficiently in Huh7.5 and Huh7.5.1 cells and had an increased infectivity in SEC14L2-expressing Huh7.5.1 cells. Incorporation of Con1 NS5B was deleterious to C-5A_7m, however Con1 5’UTR was permissive but attenuated the virus. Nucleotides G1, A4, and G35 primarily accounted for the viral attenuation without affecting RNA translation. C-5A_7m was inhibited dose-dependently by simeprevir and daclatasvir, and substitutions at A4, A29, A34, and G35 conferred resistance to miR-122 antagonism. The novel Con1 5’UTR-NS5A recombinant, adaptive mutations, and critical nucleotides described here will facilitate future studies of HCV culture systems and virus-host interaction. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
23. IFNL4 ss469415590 polymorphism contributes to treatment decisions in patients with chronic hepatitis C virus genotype 1b, but not 2a, infection.
- Author
-
Wu, Ruihong, Chi, Xiumei, Wang, Xiaomei, Sun, Haibo, Lv, Juan, Gao, Xiuzhu, Yu, Ge, Kong, Fei, Xu, Hongqin, Hua, Rui, Jiang, Jing, Sun, Bing, Zhong, Jin, Pan, Yu, and Niu, Junqi
- Subjects
- *
CHRONIC hepatitis C , *INTERFERONS , *GENETIC polymorphisms , *GENOTYPES , *ERYTHROCYTES , *THERAPEUTICS - Abstract
Recently, the dinucleotide variant ss469415590 (TT/ΔG) in a novel gene, interferon lambda 4 ( IFNL4 ), was identified as a stronger predictor of hepatitis C virus (HCV) clearance in individuals of African ancestry compared with rs12979860. We aimed to determine whether this variant contributes to treatment decisions in a Chinese population. A total of 447 chronic hepatitis C (CHC) patients (including 328 treated with interferon alpha-2b and ribavirin), 129 individuals who had spontaneously cleared HCV (SHC), and 169 healthy controls were retrospectively investigated. ss469415590 genotyping was performed using a mass spectrometry method (SEQUENOM). A higher proportion of SHC individuals carried the TT/TT genotype compared with CHC patients (95.3% vs. 88.8%, P = 0.027). In patients with HCV genotype 1b, the ss469415590 variant was independently associated with sustained virologic response (SVR) (odds ratio [OR] = 3.247, 95% confidence interval [CI] = 1.038–10.159, P = 0.043) and on-treatment virological responses, including rapid (RVR), complete early (cEVR), early (EVR), and end-of-treatment (ETVR), with a minimal OR of 3.73. Especially for patients with high viral load (≥ 4 × 10 5 IU/ml), ΔG allele carriers had a lower chance of achieving SVR compared with those carrying the TT/TT genotype (7.1% vs. 36.0%, P = 0.034, OR [95% CI] = 7.24 [1.02–318.45], negative predictive value = 92.9%). In patients with HCV genotype 2a, no significant association between the ss154949590 variant and the virological response was identified ( P > 0.05). Additionally, we found that ss154949590 was in complete linkage disequilibrium with rs12979860. In conclusion, the IFNL4 ss154949590 TT/TT genotype favors spontaneous clearance of HCV. This same variant is associated with treatment-induced clearance in patients with genotype 1b, but not 2a. ss469415590 (or rs12979860) genotyping should be considered for patients with HCV genotype 1b and high viral load when making a choice between standard dual therapy and an IFN-free direct-acting antiviral regimen. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
24. MDA5 plays a critical role in interferon response during hepatitis C virus infection.
- Author
-
Cao, Xuezhi, Ding, Qiang, Lu, Jie, Tao, Wanyin, Huang, Bing, Zhao, Yanan, Niu, Junqi, Liu, Yong-Jun, and Zhong, Jin
- Subjects
- *
THERAPEUTIC use of interferons , *HEPATITIS C virus , *CIRRHOSIS of the liver , *LIVER cancer , *GENOMICS , *RNA analysis , *CELLULAR signal transduction - Abstract
Background & Aims Hepatitis C virus (HCV) is a human pathogen that can evade host immunity to cause persistent infection, leading to liver cirrhosis and hepatocellular carcinoma. The transfected 3′UTR of HCV genomic RNA can be recognized by host protein RIG-I to activate interferon production in hepatocytes. However, it is difficult to demonstrate the RIG-I mediated sensing of HCV genomic RNA in the context of HCV infection because HCV-encoded NS3-4A protease can inactivate MAVS, a critical adaptor protein in interferon signaling. Our aim was to identify the viral sensor that triggers interferon response in hepatocytes during HCV infection. Methods We generated a hepatic cell line that stably expressed mutant MAVS resistant to the NS3-4A cleavage. This cell line allowed us to investigate the interferon signaling pathway in the context of HCV infection. By using the knockdown and knockout technology together with biochemical approaches, we were able to identify the actual viral sensor in hepatocytes during HCV infection. Results We showed that HCV infection induced robust interferon response in the cells expressing MAVS resistant to the NS3-4A cleavage. Unexpectedly, the interaction between HCV′s 3′UTR and RIG-I seemed to play a minor role in this activation, while another helicase MDA5 played a more important role in sensing HCV infection to trigger interferon response. Conclusions Our data demonstrate that MDA5 recognizes HCV to initiate host innate immune response during HCV infection. This study provides insight into how host senses HCV to initiate innate immunity during HCV infection. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
25. Corrigendum to "DDB1 is a cellular substrate of NS3/4A protease and required for hepatitis C virus replication" [Virology 435 (2013) 385–394].
- Author
-
Kang, Xi, Chen, Xi, He, Ying, Guo, Deyin, Guo, Lin, Zhong, Jin, and Shu, Hong-Bing
- Subjects
- *
HEPATITIS C virus , *VIRAL replication , *VIROLOGY , *PROTEOLYTIC enzymes - Published
- 2021
- Full Text
- View/download PDF
26. Inhibition of hepatitis C virus infection by polyoxometalates.
- Author
-
Qi, Yue, Xiang, Yu, Wang, Juan, Qi, Yanfei, Li, Juan, Niu, Junqi, and Zhong, Jin
- Subjects
- *
HEPATITIS C , *POLYOXOMETALATES , *INFLUENZA viruses , *CELL-mediated cytotoxicity , *ANTIVIRAL agents - Abstract
Highlights: [•] POM-12, a polyoxometalate compound, efficiently inhibits HCV infection. [•] POM-12 displays little cytotoxicity. [•] POM-12 is virucidal and can disrupt HCV particles. [•] POM-12 has weak inhibitory effect on VSV and influenza virus infection. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
27. Identification of a novel replication-competent hepatitis C virus variant that confers the sofosbuvir resistance.
- Author
-
Leumi, Steve, Guo, Mingzhe, Lu, Jie, Wang, Zhaoning, Gan, Tianyu, Han, Lin, Ngari, Jackline, Tong, Yimin, Xiang, Xiaogang, Xie, Qing, Wang, Lanfeng, and Zhong, Jin
- Subjects
- *
HEPATITIS C virus , *RNA replicase , *REVERSE genetics , *VIRAL mutation , *ANTIVIRAL agents ,SOFOSBUVIR - Abstract
Despite the excellent antiviral potency of direct-acting antivirals (DAAs) against hepatitis C virus (HCV), emergence of drug-resistant viral mutations remains a potential challenge. Sofobuvir (SOF), a nucleotide analog targeting HCV NS5B - RNA-dependent RNA polymerase (RdRp), constitutes a key component of many anti-HCV cocktail regimens and confers a high barrier for developing drug resistance. The serine to threonine mutation at the amino acid position 282 of NS5B (S282T) is the mostly documented SOF resistance-associated substitution (RAS), but severely hampers the virus fitness. In this study, we first developed new genotype 1b (GT1b) subgenomic replicon cells, denoted PR52D4 and PR52D9, directly from a GT1b clinical isolate. Next, we obtained SOF-resistant and replication-competent PR52D4 replicon by culturing the replicon cells in the presence of SOF. Sequencing analysis showed that the selected replicon harbored two mutations K74R and S282T in NS5B. Reverse genetics analysis showed that while PR52D4 consisting of either single mutation K74R or S282T could not replicate efficiently, the engineering of the both mutations led to a replication-competent and SOF-resistant PR52D4 replicon. Furthermore, we showed that the K74R mutation could also rescue the replication deficiency of the S282T mutation in Con1, another GT1b replicon as well as in JFH1, a GT2a replicon. Structural modeling analysis suggested that K74R might help maintain an active catalytic conformation of S282T by engaging with Y296. In conclusion, we identified the combination of two NS5B mutations S282T and K74R as a novel RAS that confers a substantial resistance to SOF while retains the HCV replication capacity. • We constructed two novel GT1b HCV replicons. • We identified the combination NS5B K74R, S282T as a new Sofosbuvir resistant associated substitution (RAS). • We proposed a structural model of interaction between K74R and S282T. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
28. Construction and characterization of infectious hepatitis C virus chimera containing structural proteins directly from genotype 1b clinical isolates.
- Author
-
Lu, Jie, Tao, Wanyin, Li, Rui, Xiang, Yu, Zhang, Nan, Xiang, Xiaogang, Xie, Qing, and Zhong, Jin
- Subjects
- *
HEPATITIS C virus , *CHIMERISM , *PROTEIN structure , *VIRAL genetics , *RECOMBINANT viruses , *VIRAL disease treatment , *VIRAL mutation - Abstract
Abstract: HCV genotype is a major determinant of clinical outcome, and GT1b HCV infection is the most difficult to treat and also the predominant genotype in East Asia and Europe. We developed 1b/JFH-1 inter-genotypic recombinants containing the structural genes (Core, E1, E2), p7 and the 1stTMD of NS2 directly from GT1b clinical isolates. Through a cloning selection strategy, we obtained 4 functional clones from 3 cases of GT1b patients' sera, which could produce infectious viruses in Huh7.5.1 cells. Sequencing analysis of recovered viruses from serial passage and reverse genetics revealed that adaptive mutations in the GT1b-originated region were enough for the enhancement of infectivity. A monoclonal antibody to E2 and original patient sera could efficiently block 3 of the viruses (26C3mt, 52B6mt and 79L9) while had little effect on 26C6mt viruses. The availability of 1b/JFH-1 chimeric viruses will be important for studies of isolate-specific neutralization and useful in evaluating antiviral therapies. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
29. Hepatitis C virus NS4B blocks the interaction of STING and TBK1 to evade host innate immunity.
- Author
-
Ding, Qiang, Cao, Xuezhi, Lu, Jie, Huang, Bing, Liu, Yong-Jun, Kato, Nobuyuki, Shu, Hong-Bing, and Zhong, Jin
- Subjects
- *
HEPATITIS C , *NATURAL immunity , *CIRRHOSIS of the liver , *LIVER cancer , *INTERFERONS , *PROTEOLYTIC enzymes , *CELLULAR signal transduction - Abstract
Background & Aims: Hepatitis C virus (HCV) is a major human viral pathogen that causes chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. In most cases, acute HCV infection becomes persistent, at least in part due to viral evasion of host innate immune response. Although HCV genomic RNA contains pathogen-associated molecular pattern (PAMP) that is able to induce host interferon responses, HCV can shut down the responses by using the viral NS3/4A protease to cleave MAVS/VISA and TRIF, two key adaptor molecules essential for the interferon signaling activation. The aim of this study was to explore a novel NS3/4A-independent mechanism HCV utilizes to evade host innate immune responses. Methods: We used the interferon promoter-reporter system to screen HCV encoded proteins for their activities to suppress the interferon signaling and to determine the molecular targets of viral proteins. Co-immunoprecipitation, confocal microscopy, and siRNA-based gene silencing were used to investigate the molecular mechanism. Results: We found that, in addition to NS3/4A, NS4B can suppress double-stranded RNA or RNA virus induced interferon activation. NS4B interacts with STING/MITA, an important molecule that mediates the HCV PAMP induced interferon signaling. Mechanistic studies indicated that NS4B disrupts the interactions between STING/MITA and TBK1. Conclusions: In conclusion, we reported an additional mechanism for HCV evasion of host interferon responses in which viral NS4B protein targets STING/MITA to suppress the interferon signaling. Our results present important evidence for the control of interferon response by HCV, and shed more light on the molecular mechanisms underlying the persistence of HCV infection. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
30. DDB1 is a cellular substrate of NS3/4A protease and required for hepatitis C virus replication
- Author
-
Kang, Xi, Chen, Xi, He, Ying, Guo, Deyin, Guo, Lin, Zhong, Jin, and Shu, Hong-Bing
- Subjects
- *
HEPATITIS C virus , *PROTEOLYTIC enzymes , *DNA damage , *DNA-binding proteins , *VIRAL replication , *TOLL-like receptors , *INTERFERONS - Abstract
Abstract: Hepatitis C virus (HCV) infection often causes long-term persistent hepatitis, which eventually leads to liver cirrhosis and hepatocellular carcinoma. HCV-encoded NS3/4A protease plays an important role in HCV immune evasion by cleaving key adapter proteins VISA and TRIF of the RIG-I-like receptors and Toll-like receptors mediated interferon (IFN) induction pathways. To further understand the roles of NS3/4A in HCV life cycle, we identified DDB1 as a cellular substrate of NS3/4A protease by biochemical purification and mass spectrometry analysis. NS3/4A interacted with DDB1 and cleaved DDB1 in HCV-infected cells. Mutagenesis indicated that NS3/4A cleaved DDB1 at the residue of C378. Overexpression of DDB1 potentiated HCV replication, whereas knockdown of DDB1 dramatically inhibited HCV replication. Furthermore, our data indicated that the cleavage of DDB1 by NS3/4A protease was required for HCV replication. Our findings suggest that DDB1 is a cellular substrate of NS3/4A required for HCV replication and provide new insight into the interaction between HCV and host cells. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
31. The N-terminal helix α0 of hepatitis C virus NS3 protein dictates the subcellular localization and stability of NS3/NS4A complex
- Author
-
He, Ying, Weng, Leiyun, Li, Rui, Li, Li, Toyoda, Tetsuya, and Zhong, Jin
- Subjects
- *
HEPATITIS C virus , *GENETIC mutation , *HELICASES , *VIRAL replication , *PROTEIN structure , *LIFE cycles (Biology) - Abstract
Abstract: The N-terminal amphipathic helix α0 of hepatitis C virus (HCV) NS3 protein is an essential structural determinant for the protein membrane association. Here, we performed functional analysis to probe the role of this helix α0 in the HCV life cycle. A point mutation M21P in this region that destroyed the helix formation disrupted the membrane association of NS3 protein and completely abolished HCV replication. Mechanistically the mutation did not affect either protease or helicase/NTPase activities of NS3, but significantly reduced the stability of NS3 protein. Furthermore, the membrane association and stability of NS3 protein can be restored by replacing the helix α0 with an amphipathic helix of the HCV NS5A protein. In summary, our data demonstrated that the amphipathic helix α0 of NS3 protein determines the proper membrane association of NS3, and this subcellular localization dictates the functional role of NS3 in the HCV life cycle. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
32. Viral sequence evolution in Chinese genotype 1b chronic hepatitis C patients experiencing unsuccessful interferon treatment
- Author
-
Xiang, Xiaogang, Lu, Jie, Dong, Zhixia, Zhou, Huijuan, Tao, Wanyin, Guo, Qing, Zhou, Xiaqiu, Bao, Shisan, Xie, Qing, and Zhong, Jin
- Subjects
- *
BIOLOGICAL evolution , *CHINESE people , *HEPATITIS C treatment , *INTERFERONS , *POLYMERASE chain reaction , *TRANSCRIPTION factors , *GENETIC mutation , *LIVER cancer , *RIBAVIRIN - Abstract
Abstract: The efficiencies of IFN-α based therapy in chronic genotype 1b HCV patients are still unsatisfied to date. The mechanisms underlining treatment failure remain unclear and controversial. To investigate HCV sequence evolution in unsuccessfully treated genotype 1b patients before, during and after the therapy, full-length open-reading-frame of HCV genomes at week 0, week 48 and year 5 in one breakthrough and one nonresponse patients were amplified by reverse transcription (RT)-nested-PCR and sequenced. Mutations were scored and analyzed according to their locations in the HCV genome. HCV sequences in the breakthrough patient displayed significantly more mutations during the one-year therapy than that in the nonresponse patient, with p7 and NS2 encoding regions having the highest mutation rates. Most of the mutations selected during the therapy phase in the breakthrough patient were maintained and few new mutations arose in the four-year post-therapy phase, suggesting these mutations might not compromise viral fitness. Altogether our data suggest that mutations occurred during the therapy phase in the breakthrough patient are likely driven by the action of interferon and ribavirin, and these mutations may have important effects on the responses to interferon based therapy in genotype 1b HCV patients. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
33. A single point mutation in E2 enhances hepatitis C virus infectivity and alters lipoprotein association of viral particles
- Author
-
Tao, Wanyin, Xu, Chunliang, Ding, Qiang, Li, Rui, Xiang, Yu, Chung, Josan, and Zhong, Jin
- Subjects
- *
GENETIC mutation , *HEPATITIS C virus , *LIPOPROTEINS , *PHENOTYPES , *HEPATITIS C , *RNA , *SECRETION , *GLYCOPROTEINS - Abstract
Abstract: Hepatitis C virus (HCV) infection is a major worldwide health problem. Our previous results showed that HCV evolved to gain the enhanced infectivity and altered buoyant density distribution during persistent infections in vitro. Here we showed that a point mutation I414T in HCV E2 was mainly responsible for these phenotypic changes. While the I414T mutation had no significant effect on HCV RNA replication and viral entry, it enhanced the production of infectious viral particles and decreased the dependency of viral entry on the levels of HCV receptors. Furthermore, we showed that the I414T mutation reduced the association of viral particles with low-density lipoprotein or very low-density lipoproteins during the virus secretion process, and the infection of the delipidated virus was more sensitive to the blockade by an anti-E2 neutralizing antibody and recombinant CD81 proteins. Our results provided more insights into understanding the roles of lipoprotein associations in HCV life cycle. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
34. Anti-flavivirus activity of polyoxometalate.
- Author
-
Qi, Yue, Han, Lin, Qi, Yanfei, Jin, Xia, Zhang, Bo, Niu, Junqi, Zhong, Jin, and Xu, Yongfen
- Subjects
- *
JAPANESE encephalitis viruses , *DENGUE viruses , *ZIKA virus , *SURFACE charges , *PHARMACOLOGY , *HEPATITIS C virus , *FLAVIVIRUSES - Abstract
Viruses in the Flaviviridae family such as Zika virus (ZIKV), dengue virus (DENV), and Japanese encephalitis virus (JEV) are major public health concerns. The development of antiviral agents against these viruses is urgently needed. We have previously discovered that the Keggin structured polyoxometalate POM-12 has potent inhibitory activity against hepatitis C virus, another member of the Flaviviridae family. In this study, we tested its antiviral activity of DENV, JEV and ZIKV, and found that POM-12 dramatically inhibited their infection with IC50 value of 1.16 μM, 1.9 μM and 0.64 μM, respectively. Mechanistic studies indicated that POM-12 directly disrupted the integrity of these virions. Moreover, POM-12 also targeted the post-entry steps of viral replication of JEV, but having no similar activities on ZIKV and DENV. The differential actions of POM-12 on these viruses suggest that surface topology and charge of virion may have influence on its drug effect, and thus POM-12 may be modified to more efficiently inhibit these and other similar viruses. • POM-12 directly inactivated DENV-2, JEV and ZIKV, possibly via disrupting the integrity of virions. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
35. Antiviral effects of simeprevir on multiple viruses.
- Author
-
Li, Zheng, Yao, Fujia, Xue, Guang, Xu, Yongfen, Niu, Junling, Cui, Mengmeng, Wang, Hongbin, Wu, Shuxian, Lu, Ailing, Zhong, Jin, and Meng, Guangxun
- Subjects
- *
HUMAN herpesvirus 1 , *ENTEROVIRUSES , *HEPATITIS C virus , *ZIKA virus , *VIRUSES ,SOFOSBUVIR - Abstract
Simeprevir was developed as a small molecular drug targeting the NS3/4A protease of hepatitis C virus (HCV). Unexpectedly, our current work discovered that Simeprevir effectively promoted the transcription of IFN-β and ISG15, inhibited the infection of host cells by multiple viruses including Zika virus (ZIKV), Enterovirus A71 (EV-A71), as well as herpes simplex virus type 1 (HSV-1). However, the inhibitory effects of Simeprevir on ZIKV, EV-A71 and HSV-1 were independent from IFN-β and ISG15. This study thus demonstrates that the application of Simeprevir can be extended to other viruses besides HCV. • Simeprevir inhibits Zika virus (ZIKV), Enterovirus A71 (EV-A71), and herpes simplex virus type 1 (HSV-1). • Simeprevir promotes the transcription of IFN-β and ISG15 in host cells. • The inhibitory effects of Simeprevir on ZIKV, EV-A71 and HSV-1 are independent from IFN-β and ISG15. • Simeprevir can be applied to control other viruses besides HCV. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
36. Construction and characterization of Genotype-3 hepatitis C virus replicon revealed critical genotype-3-specific polymorphism for drug resistance and viral fitness.
- Author
-
Guo, Mingzhe, Lu, Jie, Gan, Tianyu, Xiang, Xiaogang, Xu, Yongfen, Xie, Qing, and Zhong, Jin
- Subjects
- *
HEPATITIS C virus , *RNA replicase , *DRUG resistance , *CHRONIC hepatitis C , *AMINO acid residues , *DOUBLE-stranded RNA - Abstract
Hepatitis C virus (HCV), a major causative agent of chronic hepatitis, is a positive-stranded RNA virus and has a high degree of genetic diversity due to its error-prone RNA-dependent RNA polymerase. Development of direct-acting antiviral agents (DAAs) has greatly improved the therapeutic outcome of chronic hepatitis C patients. However, naturally existing resistance-associated variants (RAVs) or occurrence of resistance-associated substitutions (RASs) in the HCV genome may impose a challenge to the long-term success of the DAA-based therapies. Genotype-3 HCV is the most difficult genotype to treat by DAAs, but the underlying molecular mechanisms remain to be explored. Here we developed a novel genotype-3a subgenomic replicon PR87A7 by screening a HCV cDNA pool amplified from a patient serum RNA. PR87A7 replicon displayed strong resistance to anti-NS3 DAAs, mainly owing to a genotype-3-specific polymorphism 168Q in NS3. Introduction of NS3 168Q into a genotype-2a JFH1 strain rendered resistance to anti-NS3 DAAs while greatly diminished the viral replication, and yet this fitness defect can be rescued by additional genotype-3-specific polymorphism. In conclusion, we developed a novel genotype-3a subgenomic replicon by a functional screening approach, and revealed genotype-3-specfic amino acid residues that confer resistance to anti-NS3 DAAs while retaining viral fitness. • A genotype 3a replicon PR87A7 was developed by a functional screening approach. • PR87A7 replicon displays a strong resistance to anti-NS3 DAAs. • We confirmed that Q168 in NS3 is a major genotype 3-specific determinant of the resistance to anti-NS3 DAAs. • The replication defect of Q168 is rescued by additional genotype 3-specific polymorphisms. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.